UK partners with BioNTech on clinical trials of mRNA cancer therapies
pharmaphorum
JANUARY 6, 2023
The cancer immunotherapies will mainly be provided in the context of clinical trials over the alliance, which extends out to 2030, but also covers supply of commercial therapies if approved in the interim. The post UK partners with BioNTech on clinical trials of mRNA cancer therapies appeared first on.
Let's personalize your content